Epstein–Barr virus infection

QIAGEN launches QuantiFERON-EBV RUO assay, facilitating research of cell-mediated immune response to Epstein-Barr virus

Retrieved on: 
星期三, 十月 4, 2023

Venlo, the Netherlands, Oct. 04, 2023 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of its QuantiFERON-EBV RUO (Research Use Only) assay.

Key Points: 
  • Venlo, the Netherlands, Oct. 04, 2023 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of its QuantiFERON-EBV RUO (Research Use Only) assay.
  • In organ transplant recipients, EBV is associated with post-transplant lymphoproliferative disorder (PTLD), a potentially fatal complication after solid organ transplantation.
  • Measuring the T-cell response to EBV can help researchers better understand immune responses to the virus.
  • This approach is different from but complementary to traditional tests, which focus on detecting viral DNA or antibodies produced in response to the virus.

Novotech Publishes Nasopharyngeal Carcinoma Global Clinical Trial Landscape Report

Retrieved on: 
星期四, 九月 7, 2023

BOSTON, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Novotech, the leading Asia Pacific centred biotech CRO with global execution capabilities, today published the latest specialist clinical trial report – “Nasopharyngeal Carcinoma: Global Clinical Trial Landscape”.

Key Points: 
  • BOSTON, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Novotech, the leading Asia Pacific centred biotech CRO with global execution capabilities, today published the latest specialist clinical trial report – “Nasopharyngeal Carcinoma: Global Clinical Trial Landscape”.
  • According to the report, since 2018, the biopharma industry has initiated over 200 global clinical trials for nasopharyngeal carcinoma (NPC), with 60% of these located in Asia-Pacific and more than 30% in the US and Europe.
  • “NCP is the most common cancer originating from the nasopharyngeal epithelium and is mainly found in Asia and Africa.
  • Non-keratinizing nasopharyngeal carcinoma accounts for about 50% of all nasopharyngeal cancer cases.

OPKO Health’s ModeX Therapeutics Enters into Exclusive Worldwide License and Collaboration Agreement with Merck to Develop Epstein-Barr Virus Vaccine Candidate

Retrieved on: 
星期三, 三月 8, 2023

MIAMI, March 08, 2023 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) today announced that ModeX Therapeutics, Inc., an OPKO Health company, entered into an exclusive worldwide license and collaboration agreement with Merck, known as MSD outside the United States and Canada, for the development of MDX-2201, ModeX’s preclinical nanoparticle vaccine candidate targeting EBV.

Key Points: 
  • MIAMI, March 08, 2023 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) today announced that ModeX Therapeutics, Inc., an OPKO Health company, entered into an exclusive worldwide license and collaboration agreement with Merck, known as MSD outside the United States and Canada, for the development of MDX-2201, ModeX’s preclinical nanoparticle vaccine candidate targeting EBV.
  • “We are delighted to enter this collaboration with Merck to develop a vaccine against EBV, a virus that takes a profound toll on human health worldwide.
  • Targeting four proteins used by EBV to infect cells, this vaccine candidate embodies the novel multitargeting approach developed by ModeX scientists,” said Gary Nabel, M.D., Ph.D., President and Chief Executive Officer of ModeX and Chief Innovation Officer of OPKO.
  • ModeX and Merck will jointly advance MDX-2201 to an Investigational New Drug (IND) application filing, after which Merck will be responsible for clinical and regulatory activities, as well as product commercialization.

Valneva Hosts Investor Day in New York City

Retrieved on: 
星期二, 十二月 6, 2022

Saint-Herblain (France), December 06, 2022 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, is hosting an in-person investor day today in New York City to discuss the Company’s current vaccine pipeline, commercial products, and future directions.

Key Points: 
  • Saint-Herblain (France), December 06, 2022 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, is hosting an in-person investor day today in New York City to discuss the Company’s current vaccine pipeline, commercial products, and future directions.
  • While completion of the BLA submission is expected by year end, Valneva is focused on pre-commercial and market access preparations.
  • Valneva successfully generated a stabilized pre-fusion F protein antigen, which forms the basis of the proprietary vaccine candidate VLA1554.
  • Valneva is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need.

NexImmune Announces Research Collaboration with National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health (NIH)

Retrieved on: 
星期四, 十月 6, 2022

The collaboration will focus on enriching and expanding virus-specific T cell populations and determining their activity against infected human cell lines.

Key Points: 
  • The collaboration will focus on enriching and expanding virus-specific T cell populations and determining their activity against infected human cell lines.
  • The goal of this collaboration is to develop adoptive cell therapies that may benefit patients afflicted with immunological disorders related to these viral infections.
  • NexImmune is committed to developing novel therapies for the treatment of oncology, infectious disease and autoimmune disorders, said Kristi Jones, Chief Executive Officer of NexImmune.
  • This important collaboration will enable us to leverage the AIM platform to develop potentially innovative antigen-specific therapies for these patients.

Sinomab Announces IND Application of SN1011 for the Treatment of Neuromyelitis Optica Spectrum Disorder Approved by NMPA

Retrieved on: 
星期三, 八月 24, 2022

The IND approval would enable the Company to initiate the Phase II/III clinical study in China to evaluate the efficacy and safety of SN1011 for the treatment of NMOSD in China.

Key Points: 
  • The IND approval would enable the Company to initiate the Phase II/III clinical study in China to evaluate the efficacy and safety of SN1011 for the treatment of NMOSD in China.
  • SN1011 differentiates from existing BTK inhibitors currently available in the market, such as Ibrutinib, in terms of mechanism of action, affinity, selectivity and safety.
  • Currently, four IND applications of SN1011 for the treatment of SLE, PV, MS and NMOSD have been approved by NMPA respectively.
  • SinoMab BioScience Limited (stock code: 3681.HK) is dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases.

Children's Hospital of Philadelphia Appoints New Chief of Nephrology

Retrieved on: 
星期三, 七月 6, 2022

PHILADELPHIA, July 6, 2022 /PRNewswire/ -- Children's Hospital of Philadelphia (CHOP) has appointed Benjamin Laskin, MD as Chief of the Division of Nephrology in the Department of Pediatrics.

Key Points: 
  • "Dr. Laskin is a highly accomplished physician, educator, and scholar with an impressive background in nephrology.
  • Additionally, we thank Dr. Madhura Pradhan for her time as interim Chief of Nephrology and are eager to see her continue her important roles in the Division and across CHOP."
  • He completed both his pediatrics residency and pediatric nephrology fellowship at Cincinnati Children's Hospital Medical Center.
  • About Children's Hospital of Philadelphia: Children's Hospital of Philadelphia was founded in 1855 as the nation's first pediatric hospital.

SinoMab Announces IND APPLICATION FOR SN1011 ACCEPTED BY NMPA CDE

Retrieved on: 
星期四, 六月 9, 2022

The Company plans to initiate the Phase II clinical study in China upon approval of the present IND.

Key Points: 
  • The Company plans to initiate the Phase II clinical study in China upon approval of the present IND.
  • The present IND submission, once granted, will enable the Company to conduct clinical program in China for treatment of NMOSD.
  • SN1011 differentiates from existing BTK inhibitors currently available in the market in terms of mechanism of action, affinity, selectivity and safety.
  • An IND application for NMOSD for SN1011 of SinoMab has been accepted by the CDE of the NMPA, and once approved, will facilitate the clinical research and development of new drugs for NMOSD in China.

INmune Bio, Inc. Announces Research Collaboration with Chinese University of Hong Kong to Evaluate INKmune in Nasopharyngeal Cancer

Retrieved on: 
星期二, 一月 25, 2022

We are confident that these INKmune primed cells will kill NPC tumor cells very effectively and we look forward to a mutually beneficial collaboration.

Key Points: 
  • We are confident that these INKmune primed cells will kill NPC tumor cells very effectively and we look forward to a mutually beneficial collaboration.
  • History of EBV infection (commonly known as mono) and genetic polymorphisms drive the incidence of the disease, said RJ Tesi, INmune Bios Chief Executive Officer.
  • This peer-reviewed grant and international collaboration targeting what has historically been a difficult to treat solid tumor validates the versatility of INKmune.
  • Tumor-primed NK (TpNK) cells can lyse a wide variety of NK-resistant tumors including leukemias, lymphomas, myeloma, ovarian cancer, breast cancer.

Viracta Therapeutics Announces FDA Clearance of IND Application for Phase 1b/2 Trial in Epstein-Barr Virus-Positive (EBV+) Solid Tumors

Retrieved on: 
星期三, 七月 21, 2021

Food and Drug Administration(FDA) has cleared Viracta's Investigational New Drug (IND) application to proceed into a Phase 1b/2 trial in patients with EBV+ recurrent or metastatic nasopharyngeal carcinoma (RM-NPC) and other EBV+ solid tumors.

Key Points: 
  • Food and Drug Administration(FDA) has cleared Viracta's Investigational New Drug (IND) application to proceed into a Phase 1b/2 trial in patients with EBV+ recurrent or metastatic nasopharyngeal carcinoma (RM-NPC) and other EBV+ solid tumors.
  • "Clearance of this IND application is a crucial milestone that underscores the broader applicability of our therapeutic approach to treating patients with EBV-associated malignancies," said Lisa Rojkjaer, M.D., Chief Medical Officer of Viracta.
  • "EBV is the primary etiologic agent for NPC, one of the most commonly reported head and neck cancers worldwide.
  • Viracta assumes no obligation and does not intend to update these forward-looking statements, except as required by law or applicable regulation.